$172 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 85 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VCEL | New | VERICEL CORP | $8,688,000 | – | 281,346 | +100.0% | 5.05% | – |
| New | BIOGEN INCcall | $7,346,000 | – | 30,000 | +100.0% | 4.27% | – | |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $6,360,000 | – | 200,000 | +100.0% | 3.70% | – |
| DCTH | New | DELCATH SYS INC | $6,301,000 | – | 351,616 | +100.0% | 3.66% | – |
| INSM | New | INSMED INC | $5,826,000 | – | 175,000 | +100.0% | 3.38% | – |
| AMYT | New | AMRYT PHARMA PLCsponsored ads | $5,700,000 | – | 402,556 | +100.0% | 3.31% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $5,009,000 | – | 227,388 | +100.0% | 2.91% | – |
| ARVN | New | ARVINAS INC | $4,671,000 | – | 55,000 | +100.0% | 2.71% | – |
| LRMR | New | LARIMAR THERAPEUTICS INC | $4,650,000 | – | 217,203 | +100.0% | 2.70% | – |
| IMVT | New | IMMUNOVANT INC | $4,619,000 | – | 100,000 | +100.0% | 2.68% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $4,393,000 | – | 20,000 | +100.0% | 2.55% | – |
| CRIS | New | CURIS INC | $4,341,000 | – | 530,000 | +100.0% | 2.52% | – |
| HALO | New | HALOZYME THERAPEUTICS INC | $4,271,000 | – | 100,000 | +100.0% | 2.48% | – |
| TCRR | New | TCR2 THERAPEUTICS INC | $4,206,000 | – | 136,000 | +100.0% | 2.44% | – |
| STRO | New | SUTRO BIOPHARMA INC | $4,016,000 | – | 185,000 | +100.0% | 2.33% | – |
| IMGN | New | IMMUNOGEN INC | $3,870,000 | – | 600,000 | +100.0% | 2.25% | – |
| EPIX | New | ESSA PHARMA INC | $3,852,000 | – | 322,917 | +100.0% | 2.24% | – |
| CLRB | New | CELLECTAR BIOSCIENCES INC | $3,688,000 | – | 1,772,848 | +100.0% | 2.14% | – |
| CCXI | New | CHEMOCENTRYX INC | $3,329,000 | – | 53,766 | +100.0% | 1.93% | – |
| KURA | New | KURA ONCOLOGY INC | $2,939,000 | – | 90,000 | +100.0% | 1.71% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $2,928,000 | – | 17,556 | +100.0% | 1.70% | – |
| JNCE | New | JOUNCE THERAPEUTICS INC | $2,847,000 | – | 406,665 | +100.0% | 1.65% | – |
| EVGN | New | EVOGENE LTD | $2,820,000 | – | 600,000 | +100.0% | 1.64% | – |
| COGT | New | COGENT BIOSCIENCES INC | $2,640,000 | – | 235,066 | +100.0% | 1.53% | – |
| HLXA | New | HELIX ACQUISITION CORP | $2,445,000 | – | 215,071 | +100.0% | 1.42% | – |
| GH | New | GUARDANT HEALTH INC | $2,426,000 | – | 18,825 | +100.0% | 1.41% | – |
| VSTM | New | VERASTEM INC | $2,419,000 | – | 1,135,753 | +100.0% | 1.40% | – |
| AFMD | New | AFFIMED N V | $2,328,000 | – | 400,000 | +100.0% | 1.35% | – |
| RNLX | New | RENALYTIX AI PLCads | $2,260,000 | – | 141,253 | +100.0% | 1.31% | – |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $2,204,000 | – | 38,620 | +100.0% | 1.28% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $2,195,000 | – | 30,000 | +100.0% | 1.28% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $2,164,000 | – | 135,000 | +100.0% | 1.26% | – |
| TPTX | New | TURNING POINT THERAPEUTICS I | $1,966,000 | – | 16,131 | +100.0% | 1.14% | – |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $1,909,000 | – | 440,955 | +100.0% | 1.11% | – |
| CGEN | New | COMPUGEN LTDord | $1,823,000 | – | 150,550 | +100.0% | 1.06% | – |
| MORF | New | MORPHIC HLDG INC | $1,726,000 | – | 51,433 | +100.0% | 1.00% | – |
| OTIC | New | OTONOMY INC | $1,708,000 | – | 263,951 | +100.0% | 0.99% | – |
| New | TRILLIUM THERAPEUTICS INC | $1,618,000 | – | 110,000 | +100.0% | 0.94% | – | |
| ARNA | New | ARENA PHARMACEUTICALS INC | $1,537,000 | – | 20,000 | +100.0% | 0.89% | – |
| ZYME | New | ZYMEWORKS INC | $1,457,000 | – | 30,834 | +100.0% | 0.85% | – |
| NXTC | New | NEXTCURE INC | $1,417,000 | – | 130,000 | +100.0% | 0.82% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $1,414,000 | – | 16,500 | +100.0% | 0.82% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $1,407,000 | – | 80,282 | +100.0% | 0.82% | – |
| SGEN | New | SEAGEN INC | $1,315,000 | – | 7,509 | +100.0% | 0.76% | – |
| SRRK | New | SCHOLAR ROCK HLDG CORP | $1,213,000 | – | 25,000 | +100.0% | 0.70% | – |
| SURF | New | SURFACE ONCOLOGY INC | $1,201,000 | – | 130,000 | +100.0% | 0.70% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $1,182,000 | – | 5,000 | +100.0% | 0.69% | – |
| ETNB | New | 89BIO INC | $1,072,000 | – | 44,007 | +100.0% | 0.62% | – |
| KDMN | New | KADMON HLDGS INC | $1,003,000 | – | 241,756 | +100.0% | 0.58% | – |
| MREO | New | MEREO BIOPHARMA GROUP PLCads | $1,002,000 | – | 280,000 | +100.0% | 0.58% | – |
| NKTX | New | NKARTA INC | $922,000 | – | 15,000 | +100.0% | 0.54% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $908,000 | – | 35,179 | +100.0% | 0.53% | – |
| ISEE | New | IVERIC BIO INC | $899,000 | – | 130,043 | +100.0% | 0.52% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $820,000 | – | 110,000 | +100.0% | 0.48% | – |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $814,000 | – | 5,364 | +100.0% | 0.47% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $781,000 | – | 5,000 | +100.0% | 0.45% | – |
| ARDX | New | ARDELYX INC | $776,000 | – | 120,000 | +100.0% | 0.45% | – |
| New | CALITHERA BIOSCIENCES INCcall | $737,000 | – | 150,000 | +100.0% | 0.43% | – | |
| BIIB | New | BIOGEN INC | $735,000 | – | 3,000 | +100.0% | 0.43% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $726,000 | – | 25,200 | +100.0% | 0.42% | – |
| ATNM | New | ACTINIUM PHARMACEUTICALS INC | $702,000 | – | 90,000 | +100.0% | 0.41% | – |
| KALA | New | KALA PHARMACEUTICALS INC | $693,000 | – | 102,198 | +100.0% | 0.40% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $667,000 | – | 30,000 | +100.0% | 0.39% | – |
| EXAS | New | EXACT SCIENCES CORP | $662,000 | – | 5,000 | +100.0% | 0.38% | – |
| SLNO | New | SOLENO THERAPEUTICS INC | $623,000 | – | 322,798 | +100.0% | 0.36% | – |
| LPTX | New | LEAP THERAPEUTICS INC | $619,000 | – | 275,000 | +100.0% | 0.36% | – |
| MCRB | New | SERES THERAPEUTICS INC | $613,000 | – | 25,000 | +100.0% | 0.36% | – |
| GMDA | New | GAMIDA CELL LTD | $594,000 | – | 70,852 | +100.0% | 0.34% | – |
| VYNE | New | VYNE THERAPEUTICS INC | $552,000 | – | 349,624 | +100.0% | 0.32% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $548,000 | – | 10,000 | +100.0% | 0.32% | – |
| RACA | New | THERAPEUTICS ACQUISITION COR | $543,000 | – | 39,009 | +100.0% | 0.32% | – |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $519,000 | – | 10,000 | +100.0% | 0.30% | – |
| MDNA | New | MEDICENNA THERAPEUTICS CORP | $503,000 | – | 107,536 | +100.0% | 0.29% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $464,000 | – | 10,000 | +100.0% | 0.27% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $422,000 | – | 20,910 | +100.0% | 0.24% | – |
| APTX | New | APTINYX INC | $372,000 | – | 107,536 | +100.0% | 0.22% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $286,000 | – | 10,763 | +100.0% | 0.17% | – |
| New | COMPUGEN LTDcall | $242,000 | – | 20,000 | +100.0% | 0.14% | – | |
| ARQT | New | ARCUTIS BIOTHERAPEUTICS INC | $239,000 | – | 8,505 | +100.0% | 0.14% | – |
| FULC | New | FULCRUM THERAPEUTICS INC | $190,000 | – | 16,209 | +100.0% | 0.11% | – |
| PHGE | New | BIOMX INC | $88,000 | – | 13,759 | +100.0% | 0.05% | – |
| CALA | New | CALITHERA BIOSCIENCES INC | $74,000 | – | 15,000 | +100.0% | 0.04% | – |
| CHAQWS | New | CHARDAN HEALTHCR ACQSTN 2 CO*w exp 03/05/202 | $49,000 | – | 98,756 | +100.0% | 0.03% | – |
| BNGOW | New | BIONANO GENOMICS INC*w exp 08/21/202 | $21,000 | – | 10,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.